Skip to main content

It's day 12 in Trump's America and the shine of an outsider presidency has worn off already. 

The Dow Jones Industrial Average sold off for its second day in a row, its last session of the month, as divisions deepened on Capitol Hill and outcry over recent executive actions from the White House continued to drive uncertainty. 

Losses on the Dow stretched across various sectors -- the biggest losers included Goldman Sachs (GS) - Get Goldman Sachs Group, Inc. Report , Intel (INTC) - Get Intel Corporation Report and Caterpillar (CAT) - Get Caterpillar Inc. Report . The Dow slid 0.54%, or by 107 points. 

The S&P 500 was down 0.09% and The Nasdaq rose slightly, by 0.02%. The S&P 500 has fallen for the past four days.

President Donald Trump Monday night fired acting Attorney General Sally Yates for "refusing to enforce" a controversial travel ban to the U.S. on refugees and people of Muslim-majority countries. Yates had ordered Justice Department attorneys not to defend the executive order. During the campaign, Trump had floated the possibility of a Muslim ban, which conflicts with constitutional law prohibiting a test of religion.

The White House ordered on Friday the temporary ban of immigration from seven countries, including Iran and Iraq, a move deemed unconstitutional by several federal judges. The order extended to lawful residents in the U.S., including those with valid visas. The move set off a wave of protests at airports and harsh criticism from Democratic leaders.

"For the past few months a Trump presidency has been widely regarded as positive for stocks," said Nigel Green, founder and CEO of deVere Group. "But it appears that the rose-tinted glasses have come off as the travel ban for seven Muslim-majority countries has indicated to investors that there could be major geopolitical headwinds brewing as the controversy intensifies."

Democratic leaders added to the turmoil on Capitol Hill Tuesday after boycotting a vote on two of Trump's top Cabinet picks. Senate Democrats opted out of a committee vote for Department of Health and Human Services pick Tom Price and Treasury Department selection Steve Mnuchin. The boycott meant Republicans didn't have the quorum needed to proceed with a vote.

Biotech and pharmaceutical companies boosted the Nasdaq on Tuesday after Trump met with leaders in the industry and pledged to slash regulations. Meeting with the CEOs of companies including Merck (MRK) - Get Merck & Co., Inc. Report , Johnson & Johnson (JNJ) - Get Johnson & Johnson Report and Eli Lilly (LLY) - Get Eli Lilly and Company Report , Trump said approval will be a "quick process, it's not going to take 15 years." Trump also said he wants to target "astronomical" drug prices and bring drug manufacturing back to the U.S.

Scroll to Continue

TheStreet Recommends

The iShares NASDAQ Biotechnology Index ETF (IBB) - Get iShares Biotechnology ETF Report increased 2.8%, while the S&P Biotech SPDR ETF (XBI) - Get SPDR S&P BIOTECH ETF Report rose 4.2%.

Federal Reserve members convened on Tuesday for a two-day meeting, culminating in an announcement on Wednesday afternoon about interest rates. Most economists don't expect a change to rates at this meeting, though the Fed's statement could shape expectations for the rest of the year.

"There's no chance of a rate hike this week so investors are going to be poring over the sections of the Fed statement about inflation and the outlook for fiscal policy," said Luke Bartholomew, investment manager at Aberdeen Asset Management. "There's an anticipation that Trump's going to enact policies that will force the Fed to act. Equally, who he chooses to fill the vacancies on the committee will determine some of how the Fed behaves. But nothing has actually happened yet. Everyone is sitting on their hands waiting for more information."

Pfizer (PFE) - Get Pfizer Inc. Report  rose 1.3% even amid fourth-quarter earnings and guidance for weaker sales in 2017 than many anticipated. Adjusted earnings for the December-ended quarter came in at 47 cents a share, below consensus of 50 cents. CEO Ian Read said the drugmaker performed well in 2016 "despite a challenging operating environment." Pfizer anticipates full-year sales no higher than $54 billion, below average consensus of $54.5 billion.

Aetna (AET) said on Tuesday that it was considering its legal options after a federal court blocked its $37 billion takeover of Humana (HUM) - Get Humana Inc. Report . A federal judge had blocked the acquisition earlier this month on the basis that it would "substantially lessen competition in markets for individual Medical Advantage plans and health insurance sold on the public exchanges." The health insurance company also blew past earnings estimates in its recent quarter with profit of $1.63 a share, well above estimates of $1.44.

Under Armour (UA) - Get Under Armour, Inc. Class C Report slumped 23% on Tuesday morning after offering weak guidance for the full year. The athletic apparel retailer anticipates 2017 sales growth between 11% to 12% to $5.4 billion, below an anticipated $6.06 billion. Under Armour also announced the resignation of Chief Financial Offer Chip Molloy. Molloy will step down for personal reasons.

Sprint (S) - Get SentinelOne, Inc. Class A Report reported a wider-than-expected loss over its third quarter. Losses widened to $479 million, or 12 cents a share, from $142 million, or 4 cents a share, a year earlier. Analysts anticipated a loss of 8 cents a share. In more positive news, the telecom added 368,000 postpaid phone customers, its highest level in four years.

Coach (COH) rose 4% after shaking off other retailers' holiday-season woes in its recent quarter. The accessories retailer reported a 2% increase in North American sales, while international sales increased 3%. Overall revenue increased 3.8% over the holiday quarter to $1.32 billion. Adjusted earnings of 75 cents a share beat estimates by a penny.

MasterCard (MA) - Get Mastercard Incorporated Class A Report sank nearly 3% after a mixed fourth quarter. The credit card company earned an adjusted 86 cents a share over the quarter, a penny above estimates, while revenue of $2.76 billion fell short of $2.78 billion consensus. Gross dollar volume increased by 9% to $1.2 trillion over the quarter, missing analysts' target of $1.27 trillion.

Exxon Mobil (XOM) - Get Exxon Mobil Corporation Report fell short of fourth-quarter profit estimates, though recorded an increase in revenue. The oil company earned $1.68 billion, or 41 cents a share over its recent quarter, far below estimates of 70 cents a share in profit. Revenue rose to $61.1 billion from $59.8 billion in the same quarter a year earlier. Sales missed consensus of $61.4 billion. A $2 billion charge for upstream assets ate into its earnings.

UPS (UPS) - Get United Parcel Service, Inc. Class B Report sank 6% after offering a weaker full-year outlook than many anticipated. The delivery company anticipates adjusted earnings in 2017 of $5.80 to $6.10 a share, below estimates of $6.15. Adjusted earnings for its fourth quarter came in at $1.63 a share, below a target of $1.69. Results were pressured by a "shift in product mix and the continued softness in industrial production," said Chief Financial Officer Richard Peretz.